The Intellectual Property and Science business of Thomson Reuters has honoured Amplimmune, Inc. and MedImmune for their work in pharmaceutical Mergers and Acquisitions (M&A), and Isis Pharmaceuticals and Biogen Idec for biopharmaceutical licensing with the Allicense 2014 Breakthrough Award for Deal of the Year.
The winners were announced on April 29 after a public vote at 2014 Allicense, a prominent event connecting business development, licensing, and merger and acquisition (M&A) professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development. The annual award honours the top global deals in two categories: M&A and Biopharmaceutical Licensing. Five contenders in each category were nominated by Thomson Reuters deals analysts after a thorough analysis of information in Thomson Reuters Recap—the premier analysis tool for biopharmaceutical business deal making—and other criteria that examined hundreds of deals negotiated throughout 2013.
Amplimmune, Inc., the seller, and MedImmune, the buyer, were awarded the M&A Allicense 2014 Breakthrough Award for Deal of the Year for their $500 million deal around the immunological-based therapies AMP-224, AMP-110 and AMP-514.
Isis Pharmaceuticals, the seller, and Biogen Idec, the buyer, were awarded the biopharmaceutical licensing Allicense 2014 Breakthrough Award for Deal of the Year for their $100 million upfront deal around antisense technology therapies for neurological diseases.
